Charles M. Baum, M.D., Ph.D.

Board Member

Dr. Baum was the Founder, President and Chief Executive Officer of Mirati Therapeutics, and has been a Board Member since 2012 through its recent acquisition by Bristol Myers Squibb in 2024. He was President and Head of Research and Development at Mirati from 2021 to 2023 and was President and CEO from November 2012 to 2021. Prior to joining Mirati, he was at Pfizer from 2003 to 2012, most recently as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division, and prior to that, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. Dr. Baum currently serves as a member of the boards of directors at PMV Pharma, Acrivon Therapeutics, Odyssey Therapeutics and Terremoto Biosciences. He is also on the Scientific Advisory Board at ALX Oncology. Previously, he served as a member of the board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer, Inc., Immunomedics from 2019 to 2020 when it was acquired by Gilead, and BCTG Acquisition Corp from 2020 to 2021 when it merged with Tango Therapeutics. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University.